阿尔茨海默病患者海马萎缩速率与尸检TDP-43的相关性
该纵向回顾性研究分析了298例阿尔茨海默病谱系病理诊断患者的尸检脑组织与生前系列MRI,发现海马TDP-43与海马萎缩速率加快相关,且此关联在中高可能性AD患者中显著;轨迹分析提示TDP-43相关萎缩加速可能早于死亡至少10年。
要点
- 海马TDP-43阳性者海马年萎缩率高于仅杏仁核TDP-43或无TDP-43者。
- 关联主要见于神经原纤维缠结分期B3和B2者,B1者未见关联。
- TDP-43相关海马萎缩加速可能早于死亡至少10年出现。
核心结论
- TDP-43应被视为阿尔茨海默病患者海马萎缩速率增加的潜在相关因素。
- 鉴于海马萎缩在阿尔茨海默病中的重要性,亟需开发在体检测TDP-43的技术。
研究设计与样本
- 纵向回顾性研究,纳入1999年1月1日至2012年12月31日期间有生前头颅MRI的阿尔茨海默病谱系病理诊断患者尸检脑组织。
- 采用TDP-43免疫组化分组:无杏仁核或海马TDP-43、TDP-43限于杏仁核、TDP-43蔓延至海马。
- 用FreeSurfer和基于张量的形态测量计算海马体积,线性混合效应回归模型评估关联。
主要发现
- 神经原纤维缠结分期B1者中海马TDP-43与海马萎缩速率无关。
- 轨迹分析提示TDP-43相关海马萎缩速率增加可能早于死亡至少10年出现。
- FreeSurfer与基于张量的形态测量结果相似。
关键数值与推荐
- TDP-43分组:无杏仁核或海马TDP-43(n=141)、TDP-43限于杏仁核(n=33)、TDP-43蔓延至海马(n=124)。
- 神经原纤维缠结分期B3者n=205,其中海马TDP-43 n=103、仅杏仁核TDP-43 n=20、无TDP-43 n=82。
- 神经原纤维缠结分期B2者n=56,其中海马TDP-43 n=17、仅杏仁核TDP-43 n=6、无TDP-43 n=33。
- 神经原纤维缠结分期B1者n=37。
临床怎么用
- 对阿尔茨海默病患者评估海马萎缩速率时,可考虑TDP-43共病理的潜在影响。
- 目前尚无在体TDP-43检测手段,临床决策应结合现有影像与病理风险分层。
- 海马萎缩加速可能早于死亡至少10年出现,提示需关注早期影像学变化。
局限性
- 本研究为回顾性尸检队列研究,TDP-43分组依赖尸检病理。
- 研究未报告在体检测TDP-43的方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-mortem studies have not identified an association between β-amyloid or tau and rates of hippocampal atrophy in patients with Alzheimer's disease. TAR DNA binding protein 43 (TDP-43) is another protein linked to Alzheimer's disease. We aimed to investigate whether hippocampal TDP-43 is associated with increased rates of hippocampal atrophy. METHODS: In this longitudinal retrospective study, we analysed post-mortem brain tissue of all individuals with an Alzheimer's disease spectrum pathological diagnosis who had antemortem head MRI scans between Jan 1, 1999, and Dec 31, 2012, and who had been recruited into the Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic Alzheimer's Disease Patient Registry, or the Mayo Clinic Study of Aging. We did TDP-43 immunohistochemistry and classified individuals as follows: no TDP-43 in the amygdala or hippocampus; TDP-43 restricted to the amygdala; and TDP-43 spreading into the hippocampus. Each individual was also assigned a neurofibrillary tangle stage (B1-B3), relating to the likelihood of having Alzheimer's disease. We used longitudinal FreeSurfer software and tensor-based morphometry with symmetric normalisation to calculate hippocampal volume on all serial MRI scans and used linear mixed-effects regression models to estimate associations between TDP-43 and rate of hippocampal atrophy and to assess the trajectory of TDP-43-associated atrophy. FINDINGS: We identified 298 individuals meeting the inclusion criteria, with 816 usable MRI scans (spanning 1·0-11·2 years of the disease) available for analysis. 141 individuals showed no TDP-43 in the amygdala or hippocampus, 33 had TDP-43 restricted to the amygdala, and 124 had TDP-43 in the hippocampus. Among individuals with a high likelihood of having Alzheimer's disease (neurofibrillary tangle stage B3; n=205), those with hippocampal TDP-43 had faster rates of hippocampal atrophy (n=103, annual volume change -4·39%, 95% CI -4·82 to -3·95; p<0·0001) than did those with amygdala-only TDP-43 (n=20, -3·29%, -4·11 to -2·46; p<0·0001; difference -1·10%, 95% CI -2·02 to -0·19; p=0·02) and those without TDP-43 (n=82, -3·11%, -3·54 to -2·68; p<0·0001; difference -1·28%, -1·88 to -0·67; p<0·0001). Among individuals with an intermediate likelihood of having Alzheimer's disease (neurofibrillary tangle stage B2; n=56), those with hippocampal TDP-43 had faster rates of hippocampal atrophy (n=17, annual volume change -4·05%, 95% CI -5·09 to -2·99; p<0·0001) than did those with amygdala-only TDP-43 (n=6, -1·78%, -3·04 to -0·55; p=0·004; difference -2·27%, 95% CI -3·79 to -0·67; p=0·006) and those without TDP-43 (n=33, -1·63%, -2·43 to -0·83; p=0·0002; difference -2·43%, -3·66 to -1·18; p=0·0002). Hippocampal TDP-43 was not associated with the rate of hippocampal atrophy in individuals with a low likelihood of having Alzheimer's disease (neurofibrillary tangle stage B1; n=37). The trajectory analysis suggested that increased rates of TDP-43-associated hippocampal atrophy might occur at least 10 years before death. Results were similar for FreeSurfer and tensor-based morphometry. INTERPRETATION: TDP-43 should be considered as a potential factor related to increased rates of hippocampal atrophy in patients with Alzheimer's disease. Given the importance of hippocampal atrophy in Alzheimer's disease, it is imperative that techniques are developed for detection of TDP-43 in vivo. FUNDING: US National Institute on Aging (National Institutes of Health).
引用
- Josephs KA, Dickson DW, Tosakulwong N, et al. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurol. 2017. PMID: 28919059. doi:10.1016/S1474-4422(17)30284-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。